Skip to main content
OpenTrials
Completed

NCT Number: NCT01482507

Examination of the Effectiveness of Diffusion Weighted Magnetic Resonance Imaging for Identifying Poor Prognosis in Patients With Rheumatoid Arthritis

Diffusion Weighted Imaging (DWI) MRI will assist in differentiating poor prognosis bone oedema more effectively than traditional T2 weighted MRI in patients with early Rheumatoid Arthritis (RA).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Optimus Clinical Research

Kogarah, New South Wales, 2217, Australia

About this study

Assess DWI MRI in patients with early Rheumatoid Arthritis to determine whether the MRI method will assist in differentiating poor prognosis bone oedema more effectively than traditional T2 weighted MRI.

Aim 1: To compare DWI MRI with T2 weighted MRI for the discrimination of different types of bone oedema lesions in patients with early RA.

Aim 2: To examine the association between the presence of different types of bone oedema lesions detected on DWI MRI and T2 weighted MRI and the development of subsequent joint bone erosion as detected on i) MRI and ii) standard plain radiographs.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject has Rheumatoid Arthritis as defined by the ACR/Eular criteria
  • Subject is able to understand and comply with study protocol
  • Active disease as defined by DAS28> 3.0
  • Disease duration less than 12 months
  • If female, subject is either not of childbearing potential, or is of childbearing potential and is practicing an approved method of birth control throughout the study
  • subject is judged to be in good health as determined by the PI based upon results of medical history, laboratory profile and physical examination.
  • Prednisone dose 10mg or less, dose stable for 28 days prior to baseline

Exclusion criteria

  • Inflammatory arthropathy other than Rheumatoid Arthritis
  • Inactive disease as evidenced by DAS 28 CRP and / or ESR < 2.5
  • Prednisone dose greater than 10mg within 28 days prior to baseline
  • Intra-articular steroid within 28 days prior to baseline visit
  • IV Methyl-prednisone within 28 days prior to baseline visit
  • Any contra-indication to Magnetic Resonance Imaging
  • Permanent Pacemaker
  • Intracerebral aneurysm clip
  • Claustrophobia to the extent that patient cannot manage MRI investigations
  • Implanted metallic device
  • Cochlear implant

Sponsors and collaborators

Lead sponsor

Optimus Clinical Research

Other

Collaborators

  • Arthritis Australia, Abbott Australia

Registry information

Important dates

Study start
2011
Primary completion
2014
Study completion
2014
First posted
Nov 30, 2011
Registry last updated
Apr 6, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.